Galderma, the world's largest independent global dermatology company, was created in 1981 and is now present in over 100 countries with an extensive product portfolio of prescription medicines, aesthetics solutions and consumer care products. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin. For more information, please visit www.galderma.com
To play a strategic role in the worldwide launch preparation of an innovative biologic product with 2 indications in dermatology. The Global Value & Access Lead Nemolizumab will be based in Switzerland. This role will report to the Head of Market Access & HEOR and will be responsible for Market Access & Pricing activities to support the launches of Nemolizumab in Atopic Dermatitis and Prurigo Nodularis.